title: [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
abstract: OBJECTIVE
  To find sensitive and specific micro-metastic markers for prostate cancer.
  
  
  METHODS
  Using nested reverse transcription-PCR, we examined the expression of PSA, hK2 and PSMA mRNA in peripheral blood mononuclear cells of 51 patients with prostate cancer, 33 patients with benign prostate hyperplasia (BPH) and 32 normal young people.
  
  
  RESULTS
  The expression rates of PSA, hK2 and PSMA mRNA were 52.9%, 43.1% and 64.7%, respectively in prostate cancer group, and 6.2%, 7.7% and 4.6%, respectively in control group (BPH patients and normal young people) with statistical significance (P < 0.01). Although the expression rate of PSA and hK2 mRNA increased with cancer progression, there was no statistical significance among patients in different stages. The expression rate of PSMA mRNA was higher than that of PSA and hK2 mRNA in each clinical stage.
  
  
  CONCLUSIONS
  PSMA mRNA expression detected by nested RT-PCR is of greater value for the diagnosis, therapy choice and prognostic evaluation of prostate cancer patients.
authors.affiliation: Tian Jin Medical University, Tianjin 300070, China.
authors.forename: Wei-Guo
authors.initials: WG
authors.lastname: Cui
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Yong-Zhou
authors.initials: YZ
authors.lastname: Song
authors.forename: Ju
authors.initials: J
authors.lastname: Zhang
authors.forename: Li-Guo
authors.initials: LG
authors.lastname: Zhang
authors.forename: Jian-Dang
authors.initials: JD
authors.lastname: Shi
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: Qiang
mesh_terms: D000368:Aged; D000954:Antigens, Surface / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D043425:Glutamate Carboxypeptidase II / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D020840:Tissue Kallikreins / Q000097:blood*
chemical_list: D000954:Antigens, Surface; D014408:Biomarkers, Tumor; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen